The Olleyes VisuALL could alleviate limitations in testing pediatric patients and make visual field testing more accessible, cost-effective, and convenient for patients and clinicians.

Dr. Reginald Sanders named President of the American Society of Retina Specialists (ASRS)

Delaware Valley Retina Associates joins the PRISM Vision Group platform

Regulatory approval brings latest tech to Latin America. Olleyes' VR testing platform increases access to care and increases office efficiency for eye care physicians.

Study completed at Duke University shows that the VisuALL is suitable substitute for HVF when testing pediatric patients.

Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California

Space-age Technology Changes Cataract Surgery in Utah

Dr. Dan B. Tran, Founder and Medical Director at Coastal Vision Medical Group, is the first surgeon in Southern California's Orange County and Inland Empire regions to offer custom laser cataract surgery using the ALLY® Adaptive Cataract Treatment System.

In the Digital Health and Startups category at the 2023 Consumer Electronics Show (CES), Eyenovia showcased its Microdose Array Print (MAP™) Technology, the first significant advancement in ocular drug delivery methods in over a century.

Olleyes has earned their ISO and MDSAP Certifications

•• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone
•• NEXAGON was well-tolerated demonstrating a safety profile similar to vehicle
•• Amber plans to initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in Q1 2023 ••

The Microdose Array Print (MAP) Technology has shown potential in clinical trials, providing the possibility of more accurate ocular drug delivery than traditional eye droppers

This new glaucoma device is the smallest implantable medical device in the world and is the latest advancement in glaucoma care

Two highly regarded Bay Area vision specialists now offer state-of-the-art care to more patients in the San Francisco Bay Area.

FDA 510 (K) clearance was based on a pivotal clinical trial evaluating the safety and effectiveness of this novel eye-tracking-based amblyopia therapy vs eye patching, the gold standard.

With the new surgeon, the practice becomes more poised to meet the growing demand for non-invasive cosmetic care in the region

Retina Technologies is developing a modular digital vision screening platform to provide fast and affordable vision testing for early detection of eye disorders.

The small animal and exotic pet hospital continues to expand services to a new equine realm.

Leading Ophthalmology Practice, Coastal Vision Medical Group Among First to Offer EVO Visian ICL in Southern California to Provide Visual Freedom from Glasses and Contact Lenses

The newly approved connected device will facilitate patient access and communication between patients and eye care providers, collect data, and provide a platform between home and office to optimize treatment for dry eye

Digital treatment device proven non-inferior to gold-standard eye patch treatment in multi-center randomized controlled study

Wilmington Eye welcomes the team at Intracoastal Eye as the two practices seek to strengthen community access to high-quality vision care

Novel sustained-release technology has potential to eliminate the need for eye drops after cataract surgery.

The First-Ever Patient in the World Is Supplied With a Fully Digital 3D-Printed Prosthetic Eye at Moorfields Eye Hospital London

With its first fellowship trainee for oculoplastic surgery, Wilmington Eye seeks to invest in future talent in the field of ophthalmology.

With the addition of a cornea specialist, patients will have increased access to specialty vision care, improving overall healthcare outcomes for the community

An Immediate Solution for the Shortage of Certified Ophthalmic Technicians

The in-vitro studies performed in Glauconix's co-culture 3D conventional human outflow model confirm efficacy

APAC clinical trial market is projected to attain a CAGR of 8.1% till 2027 due to emergence of severe diseases, huge patient population, increasing clinical trials and R&D.

3D Human Tissue Retina Vasculature model provides a new and novel approach to rapidly and efficiently screening numerous therapies for diabetic retinopathy and diabetic macular edema.

Appointment reflects Glauconix Biosciences' expansion of their 3D Human Tissue model platform within the Ophthalmology space and brings their second commercial model closer to market